BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 17221820)

  • 1. [Medical treatment of Parkinson's disease].
    Waldvogel D
    Ther Umsch; 2007 Jan; 64(1):15-20. PubMed ID: 17221820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Idiopathic Parkinson's disease: practical hints for the treatment].
    Ludin HP
    Praxis (Bern 1994); 2005 Jul; 94(30-31):1147-50. PubMed ID: 16117469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
    Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
    Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Use of pronoran (piribedil) in Parkinson's disease: the results of a multicenter study].
    Fedorova NV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2003; 103(11):21-4. PubMed ID: 14681961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment of early Parkinson's disease].
    Delvaux V; Moonen G; Garraux G
    Rev Med Liege; 2009 Apr; 64(4):228-32. PubMed ID: 19514544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopaminergic treatment is associated with decreased body weight in patients with Parkinson's disease and dyskinesias.
    Bachmann CG; Zapf A; Brunner E; Trenkwalder C
    Eur J Neurol; 2009 Aug; 16(8):895-901. PubMed ID: 19374662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intrajejunal levodopa infusion in advanced Parkinson's disease: long-term effects on motor and non-motor symptoms and impact on patient's and caregiver's quality of life.
    Fasano A; Ricciardi L; Lena F; Bentivoglio AR; Modugno N
    Eur Rev Med Pharmacol Sci; 2012 Jan; 16(1):79-89. PubMed ID: 22338551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Continuous dopaminergic stimulation by Duodopa in advanced Parkinson's disease: Efficacy and safety].
    Annic A; Devos D; Seguy D; Dujardin K; Destée A; Defebvre L
    Rev Neurol (Paris); 2009; 165(8-9):718-27. PubMed ID: 19150100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Systematic evaluation on influence of dopaminergic therapy: on motor complications in Parkinson's disease].
    Zhou MZ; Liu ZG; Chen W; Lu LX; Wu JY; Qi C
    Zhonghua Yi Xue Za Zhi; 2009 Feb; 89(7):438-44. PubMed ID: 19567089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parkinson's disease: making the diagnosis, selecting drug therapies.
    Scharre DW; Mahler ME
    Geriatrics; 1994 Oct; 49(10):14-6, 20-3. PubMed ID: 7926845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Current treatment strategies for Parkinson's disease].
    Südmeyer M; Wojtecki L; Schnitzler A
    Fortschr Neurol Psychiatr; 2011 Dec; 79(12):733-43. PubMed ID: 22161168
    [No Abstract]   [Full Text] [Related]  

  • 12. Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect.
    Prescrire Int; 2005 Apr; 14(76):51-4. PubMed ID: 15875340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drugs for Parkinson's disease.
    Treat Guidel Med Lett; 2011 Jan; 9(101):1-6; quiz 2 p following 6. PubMed ID: 21304446
    [No Abstract]   [Full Text] [Related]  

  • 14. Current pharmacotherapeutic treatment options in Parkinson's disease.
    Rezak M
    Dis Mon; 2007 Apr; 53(4):214-22. PubMed ID: 17586328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term efficacy of rasagiline in early Parkinson's disease.
    Lew MF; Hauser RA; Hurtig HI; Ondo WG; Wojcieszek J; Goren T; Fitzer-Attas CJ
    Int J Neurosci; 2010 Jun; 120(6):404-8. PubMed ID: 20504210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Motor symptoms in Parkinson disease].
    Larsen JP; Beiske AG; Bekkelund SI; Dietrichs E; Tysnes OB; Vilming ST; Aasly JO
    Tidsskr Nor Laegeforen; 2008 Sep; 128(18):2068-71. PubMed ID: 18846123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current strategies in the treatment of Parkinson's disease and a personalized approach to management.
    Diaz NL; Waters CH
    Expert Rev Neurother; 2009 Dec; 9(12):1781-9. PubMed ID: 19951137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. When and how should treatment be started in Parkinson disease?
    Lang AE
    Neurology; 2009 Feb; 72(7 Suppl):S39-43. PubMed ID: 19221313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of motor symptoms in advanced Parkinson's disease: a practical approach.
    Maranis S; Tsouli S; Konitsiotis S
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Dec; 35(8):1795-807. PubMed ID: 21645577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical inquiries. What is the best initial treatment of Parkinson's disease?
    Schreck J; Kelsberg G; Rich J; Ward R
    J Fam Pract; 2003 Nov; 52(11):897-9. PubMed ID: 14599387
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.